Navigation Links
Upsher-Smith Announces The Launch Of Generic Clomipramine
Date:3/22/2017

MAPLE GROVE, Minn., March 22, 2017 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced the U.S. launch of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 mg, the generic equivalent to Mallinckrodt Pharmaceuticals' Anafranil® (clomipramine hydrochloride) Capsules USP.

The clomipramine hydrochloride capsules market had U.S. sales of approximately $172 million for the 12 months ending December 2016, according to IMS Health.

"Upsher-Smith has long been recognized within the pharmaceutical industry as a trusted name in generics," said Rusty Field, President, Upsher-Smith. "This is an exciting time for the Company. Upsher-Smith currently has more active ANDA programs in development than at any point in its history and is committed to expanding its portfolio of quality, high-value generic products through both internal development and strategic partnerships."

Product Information ProductStrengthNDC/List #SizeClomipramine Hydrochloride Capsules

25 mg

0832-0630-11

100-count bottleClomipramine Hydrochloride Capsules

50 mg

0832-0631-11

100-count bottleClomipramine Hydrochloride Capsules

75 mg

0832-0632-11

100-count bottle


*Clomipramine (P-XPD-1342640) is a product of Sandoz Inc., 100 College Road West, Princeton NJ 08540 (P-XPD-1342640)

For questions about ordering Clomipramine Hydrochloride Capsules, please call Upsher-Smith at 1-800-654-2299.

Suicidality and Antidepressant Drugs 

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Clomipramine hydrochloride is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) (see accompanying full Product Package Insert for Warnings, Clinical Worsening and Suicide Risk, Precautions: Information for Patients and Precautions:  Pediatric Use). 

Please refer to the full Prescribing Information, including Boxed Warning for Clomipramine Hydrochloride Capsules at www.upsher-smith.com/wp-content/uploads/Clomipramine-PI.pdf.  You can also visit www.upsher-smith.com or call 1-888-650-3789.About Upsher-Smith
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/upsher-smith-announces-the-launch-of-generic-clomipramine-300427702.html


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Upsher-Smith Enters Agreement To Expand Marketing And Distribution Of Generic Products For U.S. Market
2. Upsher-Smith And Saniona Sign Collaboration Agreement For Development Of Novel Therapeutics For Neurological Disorders
3. Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
4. Upsher-Smith Laboratories Names Rusty Field President
5. Upsher-Smith Honors 45 Innovative Pharmacists From Across The Nation
6. Upsher-Smith Honors 42 Pharmacists Nationwide For Excellence In Innovation
7. Upsher-Smith Presents New Data On The PK Equivalence Of USL255 (Extended-Release Topiramate) When Sprinkled On Food Or Swallowed Intact
8. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
9. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
10. Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
11. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... ... October 18, 2019 , ... A new study conducted ... adalimumab use in pregnancy was not associated with an increased risk for adverse ... The findings were published today in the Public Library of Science ...
(Date:10/17/2019)... ... October 17, 2019 , ... Mount ... deadly pediatric nerve cancer, who would otherwise have no treatment options, according to ... of the most common and aggressive pediatric nervous system tumors and generally has ...
(Date:10/17/2019)... ... October 17, 2019 , ... The findings of a new study ... individuals studied could be caused by toxic chemicals rather than the inhalation of oily ... With E-Cigarette Use (Vaping): A Report of Eight Cases ,” by Sanjay Mukhopadhyay, MD, ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
(Date:10/8/2019)... SAUSALITO, Calif. (PRWEB) , ... October 08, 2019 ... ... 2,100 stores - Kroger, Ralphs, QFC and Fred Meyer, King Sooper, Fry’s, Roundy’s, ... Paleo, Whole30 approved, dairy-free, grain-free & gluten-free. , “Ingredient purity and fresh ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Dr. Amir HagShenas ... in San Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ ... to save adults from living with uncomfortable symptoms, including tender and bleeding gums, and ...
(Date:10/8/2019)... ... October 08, 2019 , ... PotentiaMetrics, an Austin, ... Henderson as Chief Medical Officer. Dr. Henderson will be responsible for the development ... Henderson previously served as Chair of both the Informatics Governance and the Inpatient ...
(Date:10/8/2019)... ... October 08, 2019 , ... Smile Brands Inc. has ... compensation monitoring site, Comparably. Smile Brands, a leading dental support organization with nearly 440 ... mission to deliver Smiles for Everyone®. The Happiness Award is the latest in a ...
Breaking Medicine News(10 mins):